Replimune stock.
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies.
Replimune Group Enters Oversold Territory (REPL) Dividend Channel - Fri Feb 11, 4:10PM CST . Legendary investor Warren Buffett advises to be fearful when others are greedy, …Shares of Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) have been given an average rating of “Buy” by the six research firms that are presently covering the firm, MarketBeat.com reports.Six equities research analysts have rated the stock with a buy recommendation. The average 12 month price target among brokerages that have …Replimune Group Inc (REPL) Stock Price & News - Google Finance Home REPL • NASDAQ Replimune Group Inc Follow Share $10.39 Nov 24, 5:45:00 PM GMT-5 · USD · NASDAQ · Disclaimer search Compare... Replimune Group Inc REPL Morningstar Rating Unlock Stock XNAS Rating as of Nov 29, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Financials Valuation Operating...Today's High Today's Low 52 Week High 52 Week Low FL Technical Analysis Tools & Settings Open High Low Close Volume Volume remove 1DY | 5DY | | 3M | | YTD | | | | Max |
Replimune Group, Inc. (REPL) NasdaqGS - NasdaqGS Real Time Price. Currency in USD. Follow. 2W 10W 9M. 11.71 +0.53 (+4.74%) At close: 04:00PM EST. 11.71 0.00 (0.00%) After hours: 04:20PM EST.Earnings announcements can affect a stock's price. This table shows the stock's price the day before and the day after recent earnings reports, including the ...Complete Replimune Group Inc. stock information by Barron's. View real-time REPL stock price and news, along with industry-best analysis.
Replimune will have responsibility for operationalizing these clinical trials. ... the Company closed on an offering of common stock and pre-funded warrants raising approximately $259 million in ...WOBURN, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced a clinical development update for CERPASS, its registration-directed global randomized Phase 2 clinical trial of RP1 in combination with …
Oct 15, 2020 · Shares of Replimune Group ( REPL -2.97%) were soaring 13.3% higher as of 11:01 a.m. EDT on Thursday after rising as much as 22.4% earlier in the day. The big jump resulted from the company's ... View the basic REPL option chain and compare options of Replimune Group, Inc. on Yahoo Finance.Replimune Announces Pricing of Public Offering | Replimune BOSTON , Dec. 08, 2022 (GLOBE NEWSWIRE) -- Replimune Group , Inc. (Nasdaq: REPL), a …Nov 3, 2022 · About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death ... A high-level overview of Replimune Group, Inc. (REPL) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
If you want to keep up to date on the stock market you have a device in your pocket that makes that possible. Your phone can track everything finance-related and help keep you up to date on the world markets.
The stock of Replimune Group Inc (REPL) has gone up by 13.26% for the week, with a -15.10% drop in the past month and a -44.22% drop in the past quarter. The volatility ratio for the week is 7.61%, and the volatility levels for the past 30 days are 9.26% for REPL. The simple moving […]
To begin my analysis, Replimune's Q2 earnings revealed an upswing in expenditures, with R&D costs climbing 37% to $40.4M and SG&A expenses up 33% to $15.2M, culminating in a heightened operating ...Dec 2, 2023 · Replimune Group Inc (REPL) registered a 4.74% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 4.74% in intraday trading to $11.71 this Friday, 12/01/23, hitting a weekly high. The stock’s 5-day price performance is 12.70%, and it has moved by -18.05% in 30 days. Replimune Group, Inc. (REPL) has been beaten down lately with too much selling pressure. While the stock has lost 14.6% over the past four weeks, there is light at the end of the tunnel as it is ...Nov 8, 2023 · Our Science. Cancer involves a failure of the immune system in one of two ways: 1) the immune system is unable to recognize the tumor as foreign, and/or 2) the immune response is disabled or shut down by the tumor. Replimune is pioneering a novel class of tumor-directed oncolytic immunotherapies (TDOI) designed to kill the tumor locally, alter ... Replimune Group, Inc. (REPL) NasdaqGS - NasdaqGS Real Time Price. Currency in USD. Follow. 2W 10W 9M. 11.71 +0.53 (+4.74%) At close: 04:00PM EST. 11.71 0.00 (0.00%) After hours: 04:20PM EST.A high-level overview of Replimune Group, Inc. (REPL) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Replimune is pioneering a new generation of cancer treatments called oncolytic immunotherapies. These cleverly designed therapeutics combine multiple mechanisms of action, enhancing the ability of viruses to replicate in and kill cancer cells, generating a powerful patient-specific, systemic immune response. Oncolytic immunotherapy …
Dec 9, 2022 · In addition, in lieu of common stock to certain investors, Replimune today announced the pricing of its public offering of pre-funded warrants to purchase 4,200,000 shares of its common stock at a purchase price of $23.4999 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.0001 per share ... Exhibit 10.4 . REPLIMUNE GROUP, INC. EMPLOYEE STOCK PURCHASE PLAN . I. PURPOSE OF THE PLAN This Employee Stock Purchase Plan is intended to promote the interests of Replimune Group, Inc., a Delaware corporation, by providing eligible employees with the opportunity to acquire a proprietary interest in the Corporation through …Nov 29, 2023 · Replimune Readies $100 Million U.S. IPO. Find the latest Replimune Group, Inc. (REPL) stock analysis from Seeking Alpha’s top analysts: exclusive research and insights from bulls and bears. Replimune Group Stock Performance Shares of NASDAQ REPL opened at $11.71 on Monday. The company has a debt-to-equity ratio of 0.11, a current ratio of …At Replimune, we are developing an emerging class of cancer treatments called oncolytic immunotherapies. Oncolytic immunotherapy has the potential to treat patients with a variety of tumor types and improve on existing immunotherapies. Our goal is to revolutionize cancer treatment by making personalized therapy a practical reality for all ...Oct 1, 2021 · Replimune stock traded as low as $27.66 on August 26th, marking a near round trip from before its SITC presentation. There is plenty of competition in the oncolytic immunonocology space, but with ...
Complete Replimune Group Inc. stock information by Barron's. View real-time REPL stock price and news, along with industry-best analysis.
Replimune Group Stock Performance. Shares of REPL stock opened at $11.71 on Monday. The company has a market cap of $691.58 million, a price-to-earnings ratio of -3.80 and a beta of 1.46. The stock has a 50 day simple moving average of $13.43 and a 200-day simple moving average of $18.08.Oct 1, 2021 · Replimune stock traded as low as $27.66 on August 26th, marking a near round trip from before its SITC presentation. There is plenty of competition in the oncolytic immunonocology space, but with ... Nov 3, 2022 · About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death ... Exhibit 10.4 . REPLIMUNE GROUP, INC. EMPLOYEE STOCK PURCHASE PLAN . I. PURPOSE OF THE PLAN This Employee Stock Purchase Plan is intended to promote the interests of Replimune Group, Inc., a Delaware corporation, by providing eligible employees with the opportunity to acquire a proprietary interest in the Corporation through …Shares of Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) have been given an average rating of “Buy” by the six research firms that are presently …Find the latest Replimune Group, Inc. (REPL) stock analysis from Seeking Alpha’s top analysts: exclusive research and insights from bulls and bears.Billionaires Julian and Felix Baker have been some of the best bio-stock pickers over the past 20 years. ... (CERS-3.09%), and Replimune Group (REPL 0.31%) in the most recent quarter. All three of ...WOBURN, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced updated data from a cohort of metastatic uveal melanoma patients enrolled in the open-label, multicenter, Phase 1 study of RP2 as a single agent and in combination with nivolumab.
Shares of Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) have been given an average rating of “Buy” by the six research firms that are presently covering the firm, MarketBeat.com reports.Six equities research analysts have rated the stock with a buy recommendation. The average 12 month price target among brokerages that have …
Replimune story: Amylyx snatched the landmark approval for its ALS drug. Now its seeking cash to foot the launch bill - Endpoints News and other headlines for Replimune Group Please click here if you are not redirected within a few seconds.
Dec 7, 2022 · Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Complete Replimune Group Inc. stock information by Barron's. View real-time REPL stock price and news, along with industry-best analysis.We would like to show you a description here but the site won’t allow us.The inducement awards consist of a non-qualified stock option to purchase 82,500 shares of the Company’s common stock and restricted stock units representing 55,000 shares of the Company’s common stock. The option has an exercise of $27.20 per share, which is equal to the closing price of the Company’s common stock on the date of grant ...Event to begin at 8:00 AM ETWOBURN, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class ...At Replimune, we are developing an emerging class of cancer treatments called oncolytic immunotherapies. Oncolytic immunotherapy has the potential to treat patients with a variety of tumor types and improve on existing immunotherapies. Our goal is to revolutionize cancer treatment by making personalized therapy a practical reality for all ...About Replimune Replimune Group Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of …Replimune Group Inc (REPL) Stock Price & News - Google Finance Home REPL • NASDAQ Replimune Group Inc Follow Share $10.39 Nov 24, 5:45:00 PM GMT-5 · USD · NASDAQ · Disclaimer search Compare...Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies.Replimune Group Inc REPL Morningstar Rating Stock XNAS Rating as of Nov 24, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns …The stock of Replimune Group Inc (REPL) has gone up by 13.26% for the week, with a -15.10% drop in the past month and a -44.22% drop in the past quarter. The volatility ratio for the week is 7.61%, and the volatility levels for the past 30 days are 9.26% for REPL. The simple moving […]Replimune will supply Incyte with RP1 for the study and share costs. ... Research and development expenses included $3.3 million in stock-based compensation expenses for the first quarter ended ...
Why Replimune Stock Is Soaring Today. ... Shares of Replimune Group (REPL-2.97%) were soaring 13.3% higher as of 11:01 a.m. EDT on Thursday after rising as much as 22.4% earlier in the day. The ...Establishing ownership of stock depends on how the stock was purchased, according to the Securities and Exchange Commission. A brokerage firm may have purchased the stock or it may have been bought directly from the company.14 Des 2022 ... in its approximately $260 million public offering of 6,810,658 shares of common stock, inclusive of the underwriters' option to purchase ...Instagram:https://instagram. upcoming stock mergers 2023arkk buys todayamzn stock optionsnysearca msos A high-level overview of Replimune Group, Inc. (REPL) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. innovation refunds trustpilottastytrade futures fees Replimune's RPx platform, featuring RP1, RP2, and RP3, showcases a comprehensive and innovative approach to cancer treatment. Find out why REPL stock is a Buy. is tesla a good stock to buy 2023 Replimune Group Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune …All securities in the offering are being offered by Replimune. In addition, Replimune has granted the underwriters a 30-day option to purchase up to an additional 937,500 shares of its common stock from Replimune at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on October …View 13F filing holders of Replimune Group Inc. 13F filings are submitted quarterly to the SEC by hedge funds and other investment managers. ... *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page*** Elevate your investments Try it for free. We give you the access and tools ...